6794 — Unicocell Biomed Co Cashflow Statement
0.000.00%
- TWD3.83bn
- TWD3.34bn
- TWD31.88m
Annual cashflow statement for Unicocell Biomed Co, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -109 | -86.4 | -91.2 | -84.1 | -93.1 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 3.49 | 2.71 | 3.33 | -4.02 | -2.9 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -10.1 | -4.32 | -0.053 | -3.79 | 6.88 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -92.2 | -61.7 | -63.6 | -65.5 | -61.5 |
Capital Expenditures | -53.7 | -24 | -14.6 | -16 | -5.71 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -3.41 | 0.192 | -150 | -291 | -117 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -57.1 | -23.8 | -165 | -307 | -122 |
Financing Cash Flow Items | — | 0.019 | 0.15 | 0.17 | -0.216 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 145 | -5.66 | 151 | 339 | 174 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -3.83 | -91.2 | -77.2 | -33.7 | -10.3 |